{"schema_version":"1","generated_at":"2026-11-21T23:19:28.662Z","data_as_of":null,"url":"https://www.findmykol.com/kol/chris-derk","json_url":"https://www.findmykol.com/kol/chris-derk/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"chris-derk","name":"Chris Derk","credential":"MD","specialty":"Rheumatology","specialty_raw":"Rheumatology","therapeutic_area":"Rheumatology/Immunology","therapeutic_areas":["Rheumatology/Immunology"],"institution":"University of Pennsylvania","institution_url":"https://www.findmykol.com/institution/university-of-pennsylvania","city":"Philadelphia","state":"PA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"on_file":["npi","orcid","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Chris Derk is a Rheumatology/Immunology physician affiliated with University of Pennsylvania. OpenAlex indexes 112 publications with 3,656 citations (h-index 33); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Rheumatology/Immunology"]},"scholarship":{"works_count":112,"cited_by_count":3656,"h_index":33,"latest_activity_year":2025,"emerging":true,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT01093885","title":"Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis","phase":"NA","status":"COMPLETED","role":"Overall official","sponsor":"University of Pennsylvania","source_url":"https://clinicaltrials.gov/study/NCT01093885","trial_url":"https://www.findmykol.com/trial/NCT01093885"}],"source":"trials"},"payments":{"company_count":9,"program_years":{"first":2021,"last":null},"rows_total":14,"shown":3,"withheld":11,"rows":[{"payer":"GSK","program_year":2025,"amount_usd":77395.72,"payment_count":25},{"payer":"AstraZeneca UK Limited","program_year":2025,"amount_usd":32200,"payment_count":7},{"payer":"ZOLL Medical Corporation","program_year":2025,"amount_usd":508.33,"payment_count":1}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":9,"areas_shown":3,"areas":[{"area":"Antiparasitic","share_pct":26.6,"classes_total":1,"classes":[{"class":"Antimalarial","setting":"prescribed","share_pct":26.6,"drugs":[{"name":"Hydroxychloroquine Sulfate","share_pct":100}],"max_beneficiaries":60}]},{"area":"Cancer & immunology","share_pct":23.4,"classes_total":7,"classes":[{"class":"Folate Analog Metabolic Inhibitor","setting":"prescribed","share_pct":9,"drugs":[{"name":"Methotrexate","share_pct":100}],"max_beneficiaries":23},{"class":"TNF inhibitor","setting":"prescribed","share_pct":5.6,"drugs":[{"name":"Humira","share_pct":29.2},{"name":"Humira Pen","share_pct":26.2},{"name":"Humira(Cf) Pen","share_pct":24.6},{"name":"Enbrel","share_pct":20}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":22.3,"classes_total":2,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":21,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":54},{"class":"Aminosalicylate","setting":"prescribed","share_pct":1.3,"drugs":[{"name":"Sulfasalazine","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"mixed","data_year":2023,"office_pct":56.3,"facility_pct":43.7},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Adipose‐Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial","year":2022,"journal":"Arthritis & Rheumatology","source_url":"https://doi.org/10.1002/art.42133","status":"verified"},{"title":"Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus","year":2020,"journal":"Lara D. Veeken","source_url":"https://doi.org/10.1093/rheumatology/keaa457","status":"verified"},{"title":"HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry","year":2019,"journal":"Proceedings of the National Academy of Sciences","source_url":"https://doi.org/10.1073/pnas.1906593116","status":"verified"},{"title":"Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS)","year":2018,"journal":"CHEST Journal","source_url":"https://doi.org/10.1016/j.chest.2018.05.002","status":"verified"},{"title":"Mortality and survival in systemic sclerosis: a review of recent literature","year":2018,"journal":"Current Opinion in Rheumatology","source_url":"https://doi.org/10.1097/bor.0000000000000551","status":"verified"}],"source":"works"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Raquel Gur","slug":"raquel-gur","institution":"University of Pennsylvania","specialty":"Psychiatry","url":"https://www.findmykol.com/kol/raquel-gur","json_url":"https://www.findmykol.com/kol/raquel-gur/profile.json"},{"name":"Howard Herrmann","slug":"howard-herrmann","institution":"University of Pennsylvania","specialty":"Interventional Cardiology","url":"https://www.findmykol.com/kol/howard-herrmann","json_url":"https://www.findmykol.com/kol/howard-herrmann/profile.json"},{"name":"Robert Vonderheide","slug":"robert-vonderheide","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/robert-vonderheide","json_url":"https://www.findmykol.com/kol/robert-vonderheide/profile.json"},{"name":"David Felson","slug":"david-felson","institution":"Boston University","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/david-felson","json_url":"https://www.findmykol.com/kol/david-felson/profile.json"},{"name":"Marc Hochberg","slug":"marc-hochberg","institution":"University of Maryland School of Medicine","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/marc-hochberg","json_url":"https://www.findmykol.com/kol/marc-hochberg/profile.json"},{"name":"Philip Mease","slug":"philip-mease","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/philip-mease","json_url":"https://www.findmykol.com/kol/philip-mease/profile.json"},{"name":"Michelle Petri","slug":"michelle-petri","institution":"Johns Hopkins University School of Medicine","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/michelle-petri","json_url":"https://www.findmykol.com/kol/michelle-petri/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":11,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}